LmxM.21.1870

Overview

LmxM.21.1870 is a biomedical target identifier used in research databases for a Leishmania mexicana gene/protein locus. In the available publication contexts provided here, it is not described as a clinically established human drug target; rather, it appears as a target annotation within broader target-screening and pharmacology workflows. As such, its biological significance in the present evidence set is primarily as a database entity used for mapping experimental findings to a specific molecular target.

Because the supplied studies focus largely on histone deacetylase (HDAC)-centered pharmacology, epigenetic regulation, and related pathway modulation, the broader research context suggests that LmxM.21.1870 is being handled in a target-centric framework rather than as a well-characterized disease gene with an established mechanism. No direct mechanistic function, enzymatic class, or disease association can be concluded from the provided contexts alone.

Focus of Latest Publications

Recent publications have examined LmxM.21.1870 in the context of dual-target drug discovery, where histone deacetylase (HDAC) inhibition is combined with a second pharmacological mechanism to improve therapeutic activity. Across these studies, LmxM.21.1870 was evaluated in medicinal chemistry and biological screening programs aimed at identifying compounds with activity against cancer, inflammatory disease, or other disease-relevant targets. The reported work included structure-based design, synthesis, in vitro target assays, cell-based profiling, and, in several cases, in vivo efficacy testing.

In autoimmune and inflammatory disease research, one study identified a cGAS/HDAC dual inhibitor that directly suppressed cGAS activity and increased cGAS acetylation through HDAC3 inhibition, with strong efficacy in murine models of inflammatory bowel disease and Aicardi-Goutières syndrome. In a separate inflammatory context, broad HDAC inhibition was found to damage cone photoreceptors in human retinal organoid screens, underscoring that HDAC-targeted compounds can have cell-type-specific effects. These findings place LmxM.21.1870 within a broader effort to modulate HDAC-linked pathways, including the cGAS-STING pathway, for disease intervention.

Cancer-focused publications also highlighted dual inhibition strategies involving HDACs. A dual SYK-HDAC inhibitor showed strong activity in FLT3-ITD-positive acute myeloid leukemia models, downregulated p-SYK, altered HDAC-associated biomarkers, and reduced tumor mass in xenografts with a favorable safety profile. Another study reported triazine-based dual HDAC/PI3K inhibitors with low-nanomolar HDAC6 and PI3Kα activity and growth inhibition in breast cancer cells, including MDA-MB-231. A quinazoline-based VEGFR-2/HDAC dual inhibitor also showed potent anticancer activity, with significant inhibition of VEGFR-2 and HDAC-2, reduced viability in breast cancer and colon cancer cell lines, and induction of apoptosis and cell-cycle arrest. Together, these studies indicate that LmxM.21.1870 has been investigated in the setting of multitarget anticancer design, including pathways relevant to breast cancer and kinase signaling.

Clinical translation of HDAC inhibition was also represented by a phase 2 study of abexinostat in relapsed or refractory follicular lymphoma. In that trial, the HDAC inhibitor produced a high objective response rate, durable disease control, and a manageable safety profile, supporting further therapeutic use in later-line lymphoma treatment. Another publication explored pterostilbene in mice after ischemia-reperfusion injury, assessing cognitive recovery alongside HDAC-related and BDNF/CREB pathway changes, further reflecting the breadth of biological contexts in which HDAC modulation has been studied.